Pemetrexed Injection, Powder, Lyophilized, For Solution
Product Images NDC 70710-1655

This is a comparison of two chemotherapy regimens for treating cancer, Pemetrexed + Cisplatin (PC) and Gemcitabine + Cisplatin (GC). The data shows the survival time in months for patients receiving each regimen and the number of patients still at risk over time. The format is not very clear, and the meaning of some of the numbers and symbols is unclear, possibly due to errors.*

This appears to be a chart showing the results of two different treatments for a specific medical condition. The treatments are labeled as "Pemelrexed + Cisplatin" and "Gemcitabine + Cisplatin". The chart displays the survival time in months and the number of patients at risk for each treatment. However, some of the characters are not recognizable and it is unclear what the medical condition is or what the exact results are.*

This is a graph showing the survival probability of patients and the number of patients at risk for two treatment groups, Pemetrexed and Placebo. The x-axis represents the survival time in months, while the y-axis represents the number of patients at risk. However, the information is not entirely clear and may require additional context to draw conclusions.*

This appears to be a chart or graph illustrating survival probability for patients receiving Pemetrexed versus Placebo. Figures seem to indicate survival time in months, the number of patients involved, and various stages of cancer or medical states. Further context is not available, making it difficult to draw specific conclusions.*

This appears to be a table showing the survival probability of patients at risk who were given either Pemetrexed or Placebo. The survival time is measured in months. However, without further context or explanation, it is not possible to provide a detailed description or interpretation of the data.*

The text appears to be part of a statistical chart displaying the survival probability of patients who were administered Pometrexed and Placebo drugs. It shows the patient count and survival time in months on the x-axis and y-axis respectively. However, the information provided is incomplete and difficult to interpret without further context.*

This is a survival probability table displaying data on patients at risk grouped by treatment arms: Pemotiexed and Placebo. The number of patients at risk and their corresponding survival times in months are presented. However, the table is not complete and some parts of the text are missing or unclear.*

This appears to be a table showing survival probability, patients at risk, and survival time in months for different treatments. The treatments mentioned are Pemetroxed + Cisplatin and Cisplatin. The exact purpose or context of the table is not clear.*

This is a description of a medication with the NDC code 70710-1654-1. It is a cytotoxic agent contained in a single-dose vial. Each vial contains pemetrered disodum equivalent to 100 mg of pemetrexed for injection. The medication is manufactured by Zydus Hospira Oncology Private Limited in Ahmedabad, India, and distributed by Zydus Pharmaceuticals (USA) Inc. for intravenous use. The text also includes information on storage and disposal of the medication.*

This is a description for Pemetrexed, an intravenous medication for injection. Each vial contains 100mg of pemetrexed disodium and 106mg of mannitol USP, with sodium chloride injection added to create a solution of 25mg/mL. The solution should be diluted before use and must be used within 24 hours after reconstitution. The accompanying literature provides dosage information. Pemetrexed should be stored at controlled room temperature and refrigerated after reconstitution. The medication is a cytotoxic agent, and caution should be exercised when handling and administering it. The product is manufactured by Hospira Oncology Private Ltd. in India and distributed by Zycus Pharmaceuticals in the USA.*

This is a medication containing pemetrexed disodium, which is a cytotoxic agent for intravenous use only. Each vial contains 500 mg of pemetrexed with mannitol USP. The pH may have been adjusted using hydrochloric acid NF and/or sodium hydroxide NF. The medication should be stored at 25°C with excursions permitted to 15°-30°C. Any reconstituted or unused solution should be discarded according to the accompanying literature. The medication is manufactured by Zydus Hospira Oncology Private Limited in India and distributed by Zydus Pharmaceuticals in the USA.*

This is a description of Pemetrexed, a drug available in single-dose vials containing Pemetrexed disodium in powder form equivalent to 500mg of Pemetrexed and 500mg of Mannitol USP. The vial is required to be reconstituted by adding 20mL of 0.9% Sodium Chloride Injection, making it a solution with 25mg/mL. Hydrochloric acid NF and/or Sodium Hydroxide NF may have been added to adjust pH. The reconstituted solution must be further diluted before use. The drug is for intravenous use only and is a Cytotoxic Agent that must be stored carefully. Administer the infusion solution within 24 hours after initial reconstitution and discard the unused portion. The distribution of this drug is managed by Zydus Pharmaceuticals (USA) Inc., based in Pennington, NJ 08534.*

RRAUILS VI C:uton: Cytotec Agent is a single-dose vial containing pemetrexed disodium equivalent to 1000 mg pemetrexed, used for intravenous use only. It is stored in powder form at 25°C (77°F) and may have pH-adjusting agents such as Hydrochloric acid NF and/or sodium hydroxide NF added. The reconstituted and infusion solutions should be stored as per the accompanying literature. Unused portions must be discarded. Manufactured by Zydus Hospira Oncology Private Limited, Ahmedabad, India and distributed by Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534.*

This is a description of Pemetrexed for Injection, USP with instructions on how to reconstitute the drug before infusion. The drug comes in a single-dose vial with 1000mg of Pemetrexed disodium equivalent and is only meant for intravenous use. The reconstituted solution must be further diluted and administered within 24 hours after reconstitution. The accompanying literature provides information about dosage. The drug is a cytotoxic agent and should be stored at room temperature. Zycus Hospira Oncology Private Limited manufactures the drug, while Zydus Pharmaceuticals distributes it in the US.*